Nomura Holdings
ESPR

Nomura Holdings’s Esperion Therapeutics ESPR Stock Holding History

Nomura Holdings’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,800
Closed -$1.36M – 1356
2018
Q1 		$1.36M Buy
+18,800
New +$1.38M ﹤0.01% 967

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Nomura Holdings's ESPR Position: Q2 2025 in Review

Nomura Holdings sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 23,578 shares — an estimated $34K sold.

Nomura Holdings first reported a position in ESPR in Q1 2018 and held it in 25 quarters. The position peaked at $32.7M in Q4 2019. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Nomura Holdings reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nomura Holdings sold 23,578 Esperion Therapeutics shares in Q2 2025, an estimated $34K.
  • Nomura Holdings first reported a position in Esperion Therapeutics in Q1 2018 and held it in 25 quarters.
  • Nomura Holdings's Esperion Therapeutics position peaked at $32.7M in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Nomura Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.